Cartesian Therapeutics, Inc. (RNAC) Tops Q2 EPS by 144c

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) reported Q2 EPS of $0.54, $1.44 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $33.44 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Cartesian Therapeutics, Inc. (RNAC) click here.

You May Also Be Interested In

• NVIDIA, Mitsubishi Heavy Industries eye cooperation on AI data center cooling and power - Nikkei
• Manpower Inc. (MAN) PT Raised to $41 at UBS Ahead of Q2 Earnings
• Performance Shipping extends tanker charter at $40,500/day average rate